Concomitant
177Lu-DOTATATE
Capecitabine
Paraganglioma
Journal
EJNMMI research
ISSN: 2191-219X
Titre abrégé: EJNMMI Res
Pays: Germany
ID NLM: 101560946
Informations de publication
Date de publication:
06 Feb 2019
06 Feb 2019
Historique:
received:
04
12
2018
accepted:
28
01
2019
entrez:
7
2
2019
pubmed:
7
2
2019
medline:
7
2
2019
Statut:
epublish
Résumé
The role of concomitant peptide receptor radionuclide therapy (PRRT) and capecitabine therapy has shown benefit in gastroenteropancreatic neuroendocrine tumors. However, data reporting its role in paraganglioma (PGL) patients is lacking. The aim of this study was to evaluate the role of combined capecitabine and In this retrospective, single-institutional, single-arm, observational study, data of consecutive advanced stage PGL patients treated with concomitant Twenty-five PGL patients received an average dose of 22.86 ± 9.54 (14.43-50) GBq Our data confirm that
Sections du résumé
BACKGROUND
BACKGROUND
The role of concomitant peptide receptor radionuclide therapy (PRRT) and capecitabine therapy has shown benefit in gastroenteropancreatic neuroendocrine tumors. However, data reporting its role in paraganglioma (PGL) patients is lacking. The aim of this study was to evaluate the role of combined capecitabine and
METHODS
METHODS
In this retrospective, single-institutional, single-arm, observational study, data of consecutive advanced stage PGL patients treated with concomitant
RESULTS
RESULTS
Twenty-five PGL patients received an average dose of 22.86 ± 9.54 (14.43-50) GBq
CONCLUSIONS
CONCLUSIONS
Our data confirm that
Identifiants
pubmed: 30725219
doi: 10.1186/s13550-019-0484-y
pii: 10.1186/s13550-019-0484-y
pmc: PMC6365580
doi:
Types de publication
Journal Article
Langues
eng
Pagination
13Références
J Clin Oncol. 1999 Mar;17(3):1008-19
pubmed: 10071296
J Natl Cancer Inst. 2000 Feb 2;92(3):205-16
pubmed: 10655437
Eur J Surg Oncol. 2003 Apr;29(3):278-83
pubmed: 12657240
Surgery. 2003 Dec;134(6):956-62; discussion 962-3
pubmed: 14668728
Invest New Drugs. 1992 Nov;10(4):239-53
pubmed: 1487397
Lancet. 2005 Aug 20-26;366(9486):665-75
pubmed: 16112304
Pediatrics. 2006 Sep;118(3):1109-17
pubmed: 16951005
J Nucl Med. 2006 Oct;47(10):1599-606
pubmed: 17015894
Ann N Y Acad Sci. 2006 Aug;1073:47-51
pubmed: 17102071
Eur J Nucl Med Mol Imaging. 2008 Apr;35(4):725-33
pubmed: 18071700
Q J Nucl Med Mol Imaging. 2008 Dec;52(4):334-40
pubmed: 18480742
J Clin Oncol. 2009 Sep 1;27(25):4162-8
pubmed: 19636009
Endocr Relat Cancer. 2010 Jan 29;17(1):R53-73
pubmed: 19995807
Cancer Biother Radiopharm. 2011 Jun;26(3):395-400
pubmed: 21728843
Eur J Nucl Med Mol Imaging. 2011 Dec;38(12):2125-35
pubmed: 21892623
Horm Metab Res. 2012 May;44(5):405-10
pubmed: 22566196
Horm Metab Res. 2012 May;44(5):411-4
pubmed: 22566197
J Clin Endocrinol Metab. 2012 Nov;97(11):4040-50
pubmed: 22965939
Clin Endocrinol (Oxf). 2014 Apr;80(4):487-501
pubmed: 24118038
Eur J Nucl Med Mol Imaging. 2014 Oct;41(10):1845-51
pubmed: 24615468
Front Oncol. 2014 Jun 27;4:166
pubmed: 25019060
Med Oncol. 2016 May;33(5):47
pubmed: 27059363
Semin Nucl Med. 2016 May;46(3):203-14
pubmed: 27067501
N Engl J Med. 2017 Jan 12;376(2):125-135
pubmed: 28076709
J Surg Oncol. 2017 Mar;115(4):425-434
pubmed: 28166370
J Clin Endocrinol Metab. 2017 Sep 1;102(9):3278-3287
pubmed: 28605448
Clin Nucl Med. 2017 Nov;42(11):e457-e466
pubmed: 28872545
Qual Life Res. 1996 Dec;5(6):555-67
pubmed: 8993101